ClinicalTrials.gg
CompletedNCT02525861Updated Oct 14, 2021Results posted

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

A Phase 3 interventional study of GLASSIA in Alpha1-antitrypsin Deficiency, sponsored by Baxalta now part of Shire. Completed at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-14.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.

Enrollment
10th of 25
34 · median 30
Started
2016
with 4 others
Phase 3
7 of 25
1 open now
Registered
16th of 25
by date
Lead sponsor
4 of 25
Baxalta now part of Shire

Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 10th largest by enrollment, is one of 5 that started in 2016, is one of 7 in phase 3, and was the 16th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alpha 1-Antitrypsin

alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, or all of them as a file.
02

Study summary

The purpose of the study is 2-fold: (1) to evaluate the safety and potential immunogenicity of GLASSIA following intravenous (IV) administration via in-line filtration; and (2) to assess the effects of GLASSIA augmentation therapy on the levels of A1PI and various biomarkers in the epithelial lining fluid (ELF) following intravenous (IV) administration at a dosage of 60 milligrams per kilogram (mg/kg) Body weight (BW)/week active alpha1-proteinase inhibitor (A1PI) protein for 25 weeks in participants with emphysema due to congenital A1PI deficiency.

03

Conditions studied

  • Alpha1-antitrypsin Deficiency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants meeting the following age criteria:

    1. For participants who will undergo bronchoscopy/ bronchoalveolar lavage (BAL) procedures: 18 to 75 years of age at the time of screening.
    2. For participants who will be waived from undergoing bronchoscopy/BAL procedures: 18 years of age or older at the time of screening.
  2. Documented Alpha1-Proteinase Inhibitor (A1PI) genotype of Pi*Z/Z, Pi*Z/Null, Pi*Malton/Z, Pi*Null/Null, or other "at-risk" allelic combinations such as SZ (excluding MS and MZ without the presence of another allowable at-risk genotype) and an endogenous A1PI plasma levels of less than or equal to (\< or =)11 micrometer (μM) (\< or = 0.572 milligrams per milliliter [mg/mL]).
  3. Screening levels of endogenous plasma (antigenic) A1PI of \< or =11 μM may be collected at any time during the screening period for treatment-naive participants, or following a 4 week minimum from previous augmentation therapy in treatment-experienced participants.
  4. Participants must have at least one of the following: clinical diagnosis of emphysema, evidence of emphysema on computerized tomography (CT) scan of the chest, and/or evidence of airway obstruction which is not completely reversed with bronchodilator treatment at the time of screening.
  5. If the participant is being treated with any respiratory medications including inhaled bronchodilators, inhaled anticholinergics, inhaled , or low-dose systemic corticosteroids (prednisone \< or =10 milligram per day (mg/day) or its equivalent), the doses of the participant's medications have remained unchanged for at least 14 days prior to screening.
  6. The participant is a nonsmoker or has ceased smoking for a minimum of 13 weeks prior to screening (serum cotinine level at screening within normal range of a nonsmoker) and agrees to refrain from smoking throughout the course of the study. Participants with a positive cotinine test due to nicotine replacement therapy (example [eg], patches, chewing gum), vapor cigarettes, or snuff are eligible.
  7. If female of , the participant presents with a negative pregnancy test at screening and agrees to employ adequate measures for the duration of the study.
  8. The participant is willing and able to comply with the requirements of the protocol.
  9. The participant must have pulmonary function at the time of screening meeting both of the following:

    1. Post-bronchodilator (FEV1) greater than or equal to (> or =) 50 percentage (%) of predicted.
    2. If FEV1 is >80% predicted, then FEV1/forced vital capacity (FVC) must be \<0.7. *Note: Inclusion criterion #1a, #9a and #9b are not applicable to participants who are not required to undergo the bronchoscopy/BAL procedures.

Exclusion criteria

Exclusion Criteria:

  1. The participant is experiencing or has a history of pulmonary disease (other than (COPD), emphysema, chronic bronchitis, mild bronchiectasis, and stable asthma).
  2. The participant is experiencing or has a history of chronic severe cor pulmonale (resting mean pulmonary artery pressure > or =40 millimeters) of mercury [mm Hg]).
  3. The participant routinely produces more than 1 tablespoon of sputum per day.
  4. The participant has a history of frequent pulmonary exacerbations (greater than 2 moderate or severe exacerbations within 52 weeks prior to screening.
  5. The participant is experiencing a pulmonary exacerbation at the time of screening (participant may be rescreened 4 weeks after the clinical resolution of an exacerbation).
  6. The participant has clinically significant abnormalities (other than emphysema, chronic bronchitis, or mild bronchiectasis) detected on chest X-ray or CT scan at the time of screening (past records obtained within 52 weeks prior to screening may be used, if available).
  7. The participant has clinically significant abnormalities detected on a 12-lead (ECG) performed at the time of screening (past records obtained within 26 weeks prior to screening may be used, if available).
  8. The participant has clinically significant congestive heart failure with (NYHA) Class III/IV symptoms.
  9. The participant is experiencing an active or has a history of malignancy within 5 years prior to screening, with the exception of the following: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or stable prostate cancer not requiring treatment.
  10. The participant has a history of lung or other organ transplant, is currently on a transplant list, or has undergone major lung surgery.
  11. The participant is receiving long-term around-the-clock oxygen (O2) supplementation. (The following are allowed: short-term use of oxygen supplementation [eg, for the management of acute COPD exacerbation], O2 supplementation required during night time only, and supplemental O2 with continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BiPAP]).
  12. Known history of following infusions of human blood or blood components.
  13. Immunoglobulin A (IgA) deficiency (\<8 milligram per deciliter (mg/dL) at screening).
  14. Abnormal clinical laboratory results obtained at the time of screening meeting any of the following criteria:

    1. Serum (ALT) >3.0 times (ULN)
    2. Serum total >2.0 times ULN
    3. >2+proteinuria on urine dipstick analysis
    4. Serum creatinine >2.0 times ULN
    5. (ANC) \<1500 cells per cubic millimeter (cells/mm\^3)
    6. (Hgb) \<9.0 gram per deciliter (g/dL)
    7. count \<100,000/cubic millimeter (mm\^3)
  15. Ongoing active infection with hepatitis A virus (HAV), virus (HBV), virus (HCV), or (HIV) Type 1 or 2 infection at the time of screening.
  16. The participant has any clinically significant medical, psychiatric, or cognitive illness, or any other uncontrolled medical condition (eg, unstable angina, ) that, in the opinion of the investigator, would impede the participant's ability to comply with the study procedures, pose increased risk to the participant's safety, or confound the interpretation of study results.
  17. The participant has participated in another clinical study involving an IP or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or device during the course of this study.
  18. The participant is a family member or employee of the investigator.
  19. If female, the participant is nursing at the time of screening.

    Note: Exclusion criteria #20, #21, #22, #23, and #24 are not applicable to participants who are not required to undergo the bronchoscopy/BAL procedures.

  20. The participant has (s) to bronchoscopy such as recent myocardial infarction, unstable angina, other cardiopulmonary instability, tracheal obstruction or stenosis, moderate to severe hypoxemia or any degree of hypercapnia, unstable asthma, Stage 4 or 5 chronic kidney disease, pulmonary hypertension, severe hemorrhagic diathesis, and cervical C1/C2 arthritis.
  21. The participant has had lung surgery which may interfere with bronchoscopy.
  22. Known history of allergic/hypersensitivity reactions to medications used during and for perioperative care associated with the bronchoscopy/BAL procedures, such as local anesthetics, sedatives, pain control medications.
  23. The participant is receiving or requires long-term (>4 weeks) therapy, such as systemic at doses greater than 10 mg/day of prednisone (or its equivalent), mycophenolate mofetil, azathioprine, cyclophosphamide, and rituximab.
  24. If a participant is receiving anticoagulant or anti-platelet therapy (such as warfarin and clopidogrel), the participant is unwilling to or unable to safely discontinue anticoagulant or anti-platelet therapy within 7 days prior to until at least 24 hours after the BAL procedures. An exception is low-dose aspirin alone which is allowed.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Cohort I: GLASSIA (High-end)

    Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the high end within) at 60 milligrams per kilogram (mg/kg) BW active A1PI protein administered at a rate of 0.2 milliliters per kilogram of body weight per minute (ml/kg/min) for 25 weeks (25 planned infusions) via an IV administration.

    Biological: GLASSIA

  • Experimental
    Cohort II: GLASSIA (Low-end)

    Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the low end within the normal range) at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 ml/kg/min for 25 weeks (25 planned infusions) via an IV administration.

    Biological: GLASSIA

Interventions

  • BiologicalGLASSIA

    Participants will receive weekly IV infusions of GLASSIA at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 mL/kg/min for 25 weeks (25 planned infusions) via an IV administration.

    Also known as: Alpha1-Proteinase Inhibitor, A1PI

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution

    An Adverse Events (AEs) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Any AE that occurs on or after the first dose of IP infusion will be considered a TEAE. A TEAE that is considered potentially related to the presence of protein aggregates (particle load) in the GLASSIA solution is defined as any embolic or thrombotic event. Number of participants with TEAEs potentially related to the presence of protein aggregates (particle load) in the GLASSIA solution were reported.

    Time frame: From start of study treatment up to Week 26

  2. Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 24 Hours Following the End of IP Infusion

    An Treatment-emergent AR and suspected AR was any TEAE which met any of the following criteria: a; A TEAE that began during infusion or within 24 hours (or 1 day where time of onset is not available) following the end of IP infusion, or b; A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or c; A TEAE for which causality assessment was missing or indeterminate. Number of participants with both treatment-emergent ARs plus suspected ARs were collectively reported.

    Time frame: From start of study treatment up to 24 hours post infusion

  3. Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 72 Hours Following the End of IP Infusion

    An Treatment-emergent AR and suspected AR was any TEAE which met any of the following criteria: a; A TEAE that began during infusion or within 72 hours (or 3 days where time of onset is not available) following the end of IP infusion, or b; A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or c; A TEAE for which causality assessment was missing or indeterminate. Number of participants with both treatment-emergent ARs plus suspected ARs were collectively reported.

    Time frame: From start of study treatment up to 72 hours post infusion

  4. Number of Infusions Discontinued, Slowed, or Interrupted Due to TEAEs

    An AE was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Infusions may be interrupted or discontinued in an individual participant in the event of intolerable moderate to severe infusion-related AEs and/or at the discretion of the investigator. Number of infusions that are discontinued, slowed, or interrupted due to TEAEs were reported.

    Time frame: From start of study treatment up to Week 26

  5. Number of Participants Who Developed Binding and/or Neutralizing Anti- Alpha1-Proteinase Inhibitor(A1PI) Antibodies

    Development of Binding/Neutralizing Anti-A1PI Antibodies=Negative or missing at Baseline and confirmed positive at any post-infusion time point. Participants that had a positive result at Baseline and missing at all post-infusion time points were included as "No Development". Neutralizing anti-A1PI antibodies were only assessed in case of positive binding anti-A1PI antibodies. Anti-A1PI antibodies was detected using validated binding and neutralizing anti-A1PI antibody assays at a qualified immunoassay laboratory. Number of participants who developed binding and/or neutralizing anti-A1PI antibodies were reported.

    Time frame: From start of study treatment up to Week 26

  6. Change From Baseline in Antigenic Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid (ELF)

    Change from baseline in antigenic A1PI levels in ELF up to Week 14 was reported. Bronchoalveolar Lavage (BAL) procedures were performed at baseline and on-treatment BAL visit during GLASSIA augmentation therapy. Data for this outcome measure was analyzed and planned to be reported based on overall arm (Arms/Groups were combined as pre-specified in the study protocol).

    Time frame: Baseline up to Week 14

  7. Change From Baseline in Functional Alpha1-Proteinase Inhibitor(A1PI) Levels in Epithelial Lining Fluid (ELF)

    Change from baseline in functional A1PI (also known as Anti-Neutrophil Elastase Capacity \[ANEC\]) levels in ELF up to Week 14 was reported. BAL procedures were performed at baseline and on-treatment BAL visit during GLASSIA augmentation therapy. Data for this outcome measure was analyzed and planned to be reported based on overall arm (Arms/Groups were combined as pre-specified in the study protocol).

    Time frame: Baseline up to Week 14

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An AEs was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Any AE that occurs on or after the first dose of IP infusion will be considered a TEAE.

    Time frame: From start of study treatment up to Week 26

  2. Number of Participants Who Experienced a Shift From Normal or Clinically Non-significant Abnormal Laboratory Values at Baseline to Clinically Significant Abnormal Laboratory Values at Week 13, 25, and 26

    Clinical laboratory values included Hematology (hemoglobin, leukocytes, neutrophils, reticulocytes/erythrocytes \[Ret/Ery\], platelets); Chemistry (sodium, potassium, albumin, alanine aminotransferase \[AA\], aspartate aminotransferase \[ASA\], alkaline phosphatase \[AP\], lactate dehydrogenase \[LD\], gamma glutamyl transferase \[GGT\], bilirubin, direct bilirubin \[DB\], creatinine, creatine kinase \[CK\], glucose); Urinalysis (erythrocytes urine \[EU\], protein urine \[PU\], specific gravity \[SG\], pH) and Immunology (Complement C3, Complement C4). Assessment if a value was normal, clinically non-significant abnormal, or clinically significant abnormal was done by the investigator. Number of participants who experienced a shift from normal or clinically non-significant (NCS) abnormal laboratory values at baseline \[BL\] to clinically significant (CS) abnormal laboratory values at Week 13, 25 and 26 were reported.

    Time frame: Baseline, Week 13, 25 and 26

  3. Number of Participants With Treatment-Emergent Seroconversion or Positive Nucleic Acid Test (NAT) for Parvovirus B19 (B19V)

    Viral testing for B19V consisted of viral serology or NAT for B19V (Parvovirus B19 IgG Antibody, Parvovirus B19 IgM Antibody, Parvovirus B19 DNA Quant real-time polymerase chain reaction \[RT-PCR\]). Number of participants with treatment-emergent seroconversion or positive NAT for B19V were reported.

    Time frame: From start of study treatment up to Week 26

07

Results

Posted Oct 14, 2021

Participant flow

The study was conducted at 21 centers in the United States and 1 center in Canada between 08 Mar 2016 (first participant first visit) and 29 Jul 2020 (last participant last visit).

Participant flow — Overall Study
MilestoneCohort I: GLASSIA (High-end)Cohort II: GLASSIA (Low-end)
Started1816
Completed1714
Not completed12
Withdrew: Adverse event10
Withdrew: Withdrawal by subject01
Withdrew: Physician decision01

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution

An Adverse Events (AEs) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Any AE that occurs on or after the first dose of IP infusion will be considered a TEAE. A TEAE that is considered potentially related to the presence of protein aggregates (particle load) in the GLASSIA solution is defined as any embolic or thrombotic event. Number of participants with TEAEs potentially related to the presence of protein aggregates (particle load) in the GLASSIA solution were reported.

Time frame:
From start of study treatment up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution
ParticipantsCohort I: GLASSIA (High-end)Cohort II: GLASSIA (Low-end)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution00
PrimaryNumber of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 24 Hours Following the End of IP Infusion

An Treatment-emergent AR and suspected AR was any TEAE which met any of the following criteria: a; A TEAE that began during infusion or within 24 hours (or 1 day where time of onset is not available) following the end of IP infusion, or b; A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or c; A TEAE for which causality assessment was missing or indeterminate. Number of participants with both treatment-emergent ARs plus suspected ARs were collectively reported.

Time frame:
From start of study treatment up to 24 hours post infusion
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 24 Hours Following the End of IP Infusion
ParticipantsCohort I: GLASSIA (High-end)Cohort II: GLASSIA (Low-end)
Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 24 Hours Following the End of IP Infusion73
PrimaryNumber of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 72 Hours Following the End of IP Infusion

An Treatment-emergent AR and suspected AR was any TEAE which met any of the following criteria: a; A TEAE that began during infusion or within 72 hours (or 3 days where time of onset is not available) following the end of IP infusion, or b; A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or c; A TEAE for which causality assessment was missing or indeterminate. Number of participants with both treatment-emergent ARs plus suspected ARs were collectively reported.

Time frame:
From start of study treatment up to 72 hours post infusion
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 72 Hours Following the End of IP Infusion
ParticipantsCohort I: GLASSIA (High-end)Cohort II: GLASSIA (Low-end)
Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 72 Hours Following the End of IP Infusion107
PrimaryNumber of Infusions Discontinued, Slowed, or Interrupted Due to TEAEs

An AE was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Infusions may be interrupted or discontinued in an individual participant in the event of intolerable moderate to severe infusion-related AEs and/or at the discretion of the investigator. Number of infusions that are discontinued, slowed, or interrupted due to TEAEs were reported.

Time frame:
From start of study treatment up to Week 26
Reported as:
Number · Number of Infusions
Number of Infusions Discontinued, Slowed, or Interrupted Due to TEAEs
Number of InfusionsCohort I: GLASSIA (High-end)Cohort II: GLASSIA (Low-end)
Number of Infusions Discontinued due to TEAEs00
Number of Infusions Slowed due to TEAEs10
Number of Infusions Interrupted due to TEAEs00
PrimaryNumber of Participants Who Developed Binding and/or Neutralizing Anti- Alpha1-Proteinase Inhibitor(A1PI) Antibodies

Development of Binding/Neutralizing Anti-A1PI Antibodies=Negative or missing at Baseline and confirmed positive at any post-infusion time point. Participants that had a positive result at Baseline and missing at all post-infusion time points were included as "No Development". Neutralizing anti-A1PI antibodies were only assessed in case of positive binding anti-A1PI antibodies. Anti-A1PI antibodies was detected using validated binding and neutralizing anti-A1PI antibody assays at a qualified immunoassay laboratory. Number of participants who developed binding and/or neutralizing anti-A1PI antibodies were reported.

Time frame:
From start of study treatment up to Week 26
Reported as:
Count of participants · Participants
Number of Participants Who Developed Binding and/or Neutralizing Anti- Alpha1-Proteinase Inhibitor(A1PI) Antibodies
ParticipantsCohort I: GLASSIA (High-end)Cohort II: GLASSIA (Low-end)
Number of participants with binding Anti-A1PI antibodies11
Number of participants with neutralizing Anti-A1PI antibodies11
PrimaryChange From Baseline in Antigenic Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid (ELF)

Change from baseline in antigenic A1PI levels in ELF up to Week 14 was reported. Bronchoalveolar Lavage (BAL) procedures were performed at baseline and on-treatment BAL visit during GLASSIA augmentation therapy. Data for this outcome measure was analyzed and planned to be reported based on overall arm (Arms/Groups were combined as pre-specified in the study protocol).

Time frame:
Baseline up to Week 14
Reported as:
Median · Micromolar (mcM)
Change From Baseline in Antigenic Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid (ELF)
Micromolar (mcM)All GLASSIA 60 mg/kg/Week
Change From Baseline in Antigenic Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid (ELF)0.515 (0.08 to 2.41)
Statistical analysis
  • All GLASSIA 60 mg/kg/Week · Mixed-effects model · p = <0.001 · Geometric mean ratio: 5.398
PrimaryChange From Baseline in Functional Alpha1-Proteinase Inhibitor(A1PI) Levels in Epithelial Lining Fluid (ELF)

Change from baseline in functional A1PI (also known as Anti-Neutrophil Elastase Capacity \[ANEC\]) levels in ELF up to Week 14 was reported. BAL procedures were performed at baseline and on-treatment BAL visit during GLASSIA augmentation therapy. Data for this outcome measure was analyzed and planned to be reported based on overall arm (Arms/Groups were combined as pre-specified in the study protocol).

Time frame:
Baseline up to Week 14
Reported as:
Median · mcM
Change From Baseline in Functional Alpha1-Proteinase Inhibitor(A1PI) Levels in Epithelial Lining Fluid (ELF)
mcMAll GLASSIA 60 mg/kg/Week
Change From Baseline in Functional Alpha1-Proteinase Inhibitor(A1PI) Levels in Epithelial Lining Fluid (ELF)0.256 (-0.28 to 1.54)
Statistical analysis
  • All GLASSIA 60 mg/kg/Week · mixed-effects model · p = <0.001 · Geometric mean ratio: 2.259
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AEs was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Any AE that occurs on or after the first dose of IP infusion will be considered a TEAE.

Time frame:
From start of study treatment up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsCohort I: GLASSIA (High-end)Cohort II: GLASSIA (Low-end)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)139
SecondaryNumber of Participants Who Experienced a Shift From Normal or Clinically Non-significant Abnormal Laboratory Values at Baseline to Clinically Significant Abnormal Laboratory Values at Week 13, 25, and 26

Clinical laboratory values included Hematology (hemoglobin, leukocytes, neutrophils, reticulocytes/erythrocytes \[Ret/Ery\], platelets); Chemistry (sodium, potassium, albumin, alanine aminotransferase \[AA\], aspartate aminotransferase \[ASA\], alkaline phosphatase \[AP\], lactate dehydrogenase \[LD\], gamma glutamyl transferase \[GGT\], bilirubin, direct bilirubin \[DB\], creatinine, creatine kinase \[CK\], glucose); Urinalysis (erythrocytes urine \[EU\], protein urine \[PU\], specific gravity \[SG\], pH) and Immunology (Complement C3, Complement C4). Assessment if a value was normal, clinically non-significant abnormal, or clinically significant abnormal was done by the investigator. Number of participants who experienced a shift from normal or clinically non-significant (NCS) abnormal laboratory values at baseline \[BL\] to clinically significant (CS) abnormal laboratory values at Week 13, 25 and 26 were reported.

Time frame:
Baseline, Week 13, 25 and 26
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Shift From Normal or Clinically Non-significant Abnormal Laboratory Values at Baseline to Clinically Significant Abnormal Laboratory Values at Week 13, 25, and 26
ParticipantsCohort I: GLASSIA (High-end)Cohort II: GLASSIA (Low-end)
Hemoglobin: Normal at BL→Abnormal-CS at Week 1300
Hemoglobin: Abnormal-NCS at BL→Abnormal-CS at Week 1300
Hemoglobin: Normal at BL→Abnormal-CS at Week 2500
Hemoglobin: Abnormal-NCS at BL→Abnormal-CS at Week 2500
Hemoglobin: Normal at BL→Abnormal-CS at Week 2600
Hemoglobin: Abnormal-NCS at BL→Abnormal-CS at Week 2600
Leukocytes: Normal at BL→Abnormal-CS at Week 1300
Leukocytes: Abnormal-NCS at BL→Abnormal-CS at Week 1300
Leukocytes: Normal at BL→Abnormal-CS at Week 2500
Leukocytes: Abnormal-NCS at BL→Abnormal-CS at Week 2500
Leukocytes: Normal at BL→Abnormal-CS at Week 2600
Leukocytes: Abnormal-NCS at BL→Abnormal-CS at Week 2600
Neutrophils: Normal at BL→Abnormal-CS at Week 1300
Neutrophils: Abnormal-NCS at BL→Abnormal-CS at Week 1300
Neutrophils: Normal at BL→Abnormal-CS at Week 2510
Neutrophils: Abnormal-NCS at BL→Abnormal-CS at Week 2500
Neutrophils: Normal at BL→Abnormal-CS at Week 2600
Neutrophils: Abnormal-NCS at BL→Abnormal-CS at Week 2600
Ret/Ery: Normal at BL→Abnormal-CS at Week 1310
Ret/Ery: Abnormal-NCS at BL→Abnormal-CS at Week 1300
Ret/Ery: Normal at BL→Abnormal-CS at Week 2500
Ret/Ery: Abnormal-NCS at BL→Abnormal-CS at Week 2500
Ret/Ery: Normal at BL→Abnormal-CS at Week 2610
Ret/Ery: Abnormal-NCS at BL→Abnormal-CS at Week 2600
Platelets: Normal at BL→Abnormal-CS at Week 1300
Platelets: Abnormal-NCS at BL→Abnormal-CS at Week 1300
Platelets: Normal at BL→Abnormal-CS at Week 2500
Platelets: Abnormal-NCS at BL→Abnormal-CS at Week 2500
Platelets: Normal at BL→Abnormal-CS at Week 2600
Platelets: Abnormal-NCS at BL→Abnormal-CS at Week 2600
Sodium: Normal at BL→Abnormal-CS at Week 1300
Sodium: Abnormal-NCS at BL→Abnormal-CS at Week 1300
Sodium: Normal at BL→Abnormal-CS at Week 2500
Sodium: Abnormal-NCS at BL→Abnormal-CS at Week 2500
Sodium: Normal at BL→Abnormal-CS at Week 2600
Sodium: Abnormal-NCS at BL→Abnormal-CS at Week 2600
Potassium: Normal at BL→Abnormal-CS at Week 1300
Potassium: Abnormal-NCS at BL→Abnormal-CS at Week 1300
Potassium: Normal at BL→Abnormal-CS at Week 2500
Potassium: Abnormal-NCS at BL→Abnormal-CS at Week 2500
Potassium: Normal at BL→Abnormal-CS at Week 2600
Potassium: Abnormal-NCS at BL→Abnormal-CS at Week 2600
Albumin: Normal at BL→Abnormal-CS at Week 1300
Albumin: Abnormal-NCS at BL→Abnormal-CS at Week 1300
Albumin: Normal at BL→Abnormal-CS at Week 2500
Albumin: Abnormal-NCS at BL→Abnormal-CS at Week 2500
Albumin: Normal at BL→Abnormal-CS at Week 2600
Albumin: Abnormal-NCS at BL→Abnormal-CS at Week 2600
AA: Normal at BL→Abnormal-CS at Week 1300
AA: Abnormal-NCS at BL→Abnormal-CS at Week 1300
AA: Normal at BL→Abnormal-CS at Week 2500
AA: Abnormal-NCS at BL→Abnormal-CS at Week 2500
AA: Normal at BL→Abnormal-CS at Week 2600
AA: Abnormal-NCS at BL→Abnormal-CS at Week 2600
ASA: Normal at BL→Abnormal-CS at Week 1300
ASA: Abnormal-NCS at BL→Abnormal-CS at Week 1300
ASA: Normal at BL→Abnormal-CS at Week 2500
ASA: Abnormal-NCS at BL→Abnormal-CS at Week 2500
ASA: Normal at BL→Abnormal-CS at Week 2600
ASA: Abnormal-NCS at BL→Abnormal-CS at Week 2600
AP: Normal at BL→Abnormal-CS at Week 1300
AP: Abnormal-NCS at BL→Abnormal-CS at Week 1300
AP: Normal at BL→Abnormal-CS at Week 2500
AP: Abnormal-NCS at BL→Abnormal-CS at Week 2500
AP: Normal at BL→Abnormal-CS at Week 2600
AP: Abnormal-NCS at BL→Abnormal-CS at Week 2600
LD: Normal at BL→Abnormal-CS at Week 1300
LD: Abnormal-NCS at BL→Abnormal-CS at Week 1300
LD: Normal at BL→Abnormal-CS at Week 2500
LD: Abnormal-NCS at BL→Abnormal-CS at Week 2500
LD: Normal at BL→Abnormal-CS at Week 2600
LD: Abnormal-NCS at BL→Abnormal-CS at Week 2600
GGT: Normal at BL→Abnormal-CS at Week 1300
GGT: Abnormal-NCS at BL→Abnormal-CS at Week 1300
GGT: Normal at BL→Abnormal-CS at Week 2500
GGT: Abnormal-NCS at BL→Abnormal-CS at Week 2500
GGT: Normal at BL→Abnormal-CS at Week 2600
GGT: Abnormal-NCS at BL→Abnormal-CS at Week 2600
Bilirubin: Normal at BL→Abnormal-CS at Week 1300
Bilirubin: Abnormal-NCS at BL→Abnormal-CS at Week 1300
Bilirubin: Normal at BL→Abnormal-CS at Week 2500
Bilirubin: Abnormal-NCS at BL→Abnormal-CS at Week 2500
Bilirubin: Normal at BL→Abnormal-CS at Week 2600
Bilirubin: Abnormal-NCS at BL→Abnormal-CS at Week 2600
DB: Normal at BL→Abnormal-CS at Week 1300
DB: Abnormal-NCS at BL→Abnormal-CS at Week 1300
DB: Normal at BL→Abnormal-CS at Week 2500
DB: Abnormal-NCS at BL→Abnormal-CS at Week 2500
DB: Normal at BL→Abnormal-CS at Week 2600
DB: Abnormal-NCS at BL→Abnormal-CS at Week 2600
Creatinine: Normal at BL→Abnormal-CS at Week 1300
Creatinine: Abnormal-NCS at BL→Abnormal-CS at Week 1300
Creatinine: Normal at BL→Abnormal-CS at Week 2500
Creatinine: Abnormal-NCS at BL→Abnormal-CS at Week 2500
Creatinine: Normal at BL→Abnormal-CS at Week 2600
Creatinine: Abnormal-NCS at BL→Abnormal-CS at Week 2600
CK: Normal at BL→Abnormal-CS at Week 1300
CK: Abnormal-NCS at BL→Abnormal-CS at Week 1300
CK: Normal at BL→Abnormal-CS at Week 2510
CK: Abnormal-NCS at BL→Abnormal-CS at Week 2500
CK: Normal at BL→Abnormal-CS at Week 2600
CK: Abnormal-NCS at BL→Abnormal-CS at Week 2600
Glucose: Normal at BL→Abnormal-CS at Week 1300
Glucose: Abnormal-NCS at BL→Abnormal-CS at Week 1300
Glucose: Normal at BL→Abnormal-CS at Week 2500
Glucose: Abnormal-NCS at BL→Abnormal-CS at Week 2500
Glucose: Normal at BL→Abnormal-CS at Week 2600
Glucose: Abnormal-NCS at BL→Abnormal-CS at Week 2600
EU: Normal at BL→Abnormal-CS at Week 1300
EU: Abnormal-NCS at BL→Abnormal-CS at Week 1300
EU: Normal at BL→Abnormal-CS at Week 2600
EU: Abnormal-NCS at BL→Abnormal-CS at Week 2600
PU: Normal at BL→Abnormal-CS at Week 1300
PU: Abnormal-NCS at BL→Abnormal-CS at Week 1300
PU: Normal at BL→Abnormal-CS at Week 2500
PU: Abnormal-NCS at BL→Abnormal-CS at Week 2500
PU: Normal at BL→Abnormal-CS at Week 2600
PU: Abnormal-NCS at BL→Abnormal-CS at Week 2600
SG: Normal at BL→Abnormal-CS at Week 1300
SG: Abnormal-NCS at BL→Abnormal-CS at Week 1300
SG: Normal at BL→Abnormal-CS at Week 2500
SG: Abnormal-NCS at BL→Abnormal-CS at Week 2500
SG: Normal at BL→Abnormal-CS at Week 2600
SG: Abnormal-NCS at BL→Abnormal-CS at Week 2600
pH: Normal at BL→Abnormal-CS at Week 1300
pH: Abnormal-NCS at BL→Abnormal-CS at Week 1300
pH: Normal at BL→Abnormal-CS at Week 2500
pH: Abnormal-NCS at BL→Abnormal-CS at Week 2500
pH: Normal at BL→Abnormal-CS at Week 2600
pH: Abnormal-NCS at BL→Abnormal-CS at Week 2600
C3: Normal at BL→Abnormal-CS at Week 1300
C3: Abnormal-NCS at BL→Abnormal-CS at Week 1300
C3: Normal at BL→Abnormal-CS at Week 2500
C3: Abnormal-NCS at BL→Abnormal-CS at Week 2500
C3: Normal at BL→Abnormal-CS at Week 2600
C3: Abnormal-NCS at BL→Abnormal-CS at Week 2600
C4: Normal at BL→Abnormal-CS at Week 1300
C4: Abnormal-NCS at BL→Abnormal-CS at Week 1300
C4: Normal at BL→Abnormal-CS at Week 2500
C4: Abnormal-NCS at BL→Abnormal-CS at Week 2500
C4: Normal at BL→Abnormal-CS at Week 2600
C4: Abnormal-NCS at BL→Abnormal-CS at Week 2600
SecondaryNumber of Participants With Treatment-Emergent Seroconversion or Positive Nucleic Acid Test (NAT) for Parvovirus B19 (B19V)

Viral testing for B19V consisted of viral serology or NAT for B19V (Parvovirus B19 IgG Antibody, Parvovirus B19 IgM Antibody, Parvovirus B19 DNA Quant real-time polymerase chain reaction \[RT-PCR\]). Number of participants with treatment-emergent seroconversion or positive NAT for B19V were reported.

Time frame:
From start of study treatment up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Seroconversion or Positive Nucleic Acid Test (NAT) for Parvovirus B19 (B19V)
ParticipantsCohort I: GLASSIA (High-end)Cohort II: GLASSIA (Low-end)
Number of participants with parvovirus B19 IgG antibody01
Number of participants with parvovirus B19 IgM antibody00
Number of participants with Parvovirus B19 DNA Quant RT-PCR00

Adverse events

Collected over From start of study treatment up to Week 26. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GLASSIA (High-end)0/18 (0%)1/18 (5.6%)13/18 (72.2%)
GLASSIA (Low-end)0/16 (0%)1/16 (6.3%)9/16 (56.3%)
Most frequent serious events
Most frequent serious events
EventGLASSIA (High-end)GLASSIA (Low-end)
PneumothoraxRespiratory, thoracic and mediastinal disorders0/181/16
InfluenzaInfections and infestations1/180/16
PneumoniaInfections and infestations1/180/16
Most frequent other events
Showing 10 of 52
Most frequent other events
EventGLASSIA (High-end)GLASSIA (Low-end)
NasopharyngitisInfections and infestations5/181/16
Upper respiratory tract infectionInfections and infestations0/183/16
DiarrhoeaGastrointestinal disorders3/180/16
SinusitisInfections and infestations0/182/16
NauseaGastrointestinal disorders2/180/16
VomitingGastrointestinal disorders2/180/16
Back painMusculoskeletal and connective tissue disorders2/181/16
CoughRespiratory, thoracic and mediastinal disorders2/180/16
DyspnoeaRespiratory, thoracic and mediastinal disorders2/181/16
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/181/16

Baseline characteristics

Safety analysis set consisted of all enrolled participants who received any amount of investigational product (IP), regardless of protocol deviations or non-adherence to study procedures.

Age, Continuous
Age, Continuous(Years)Cohort I: GLASSIA (High-end)Cohort II: GLASSIA (Low-end)Total
Mean57.9 ± 8.9558.9 ± 9.3258.4 ± 9.00
Sex: Female, Male
Sex: Female, Male(Participants)Cohort I: GLASSIA (High-end)Cohort II: GLASSIA (Low-end)Total
Female8614
Male101020
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort I: GLASSIA (High-end)Cohort II: GLASSIA (Low-end)Total
Hispanic or Latino123
Not Hispanic or Latino171431
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort I: GLASSIA (High-end)Cohort II: GLASSIA (Low-end)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White181634
More than one race000
Unknown or Not Reported000
08

Study locations

18 sites
  • Arizona Board of Regents, University of Arizona
    Tucson, Arizona 85724, United States
  • UCLA Medical Center
    Los Angeles, California 90024, United States
  • Cedars Sinai Medical Center, Division of Pulmonary and Critical Care Medicine
    Los Angeles, California 90048, United States
  • University of California Davis Health System
    Sacramento, California 95817, United States
  • University of Miami
    Miami, Florida 33136, United States
  • DBC Research Corp, Pembroke Pines
    Tamarac, Florida 33321, United States
  • Cleveland Clinic Florida - Weston
    Weston, Florida 33331, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • LaPorte County Institute for Clinical Research, Inc.
    Michigan City, Indiana 46360, United States
  • Pulmonary Critical Care Associates of Baltimore
    Towson, Maryland 21286, United States
  • Hannibal Clinic
    Hannibal, Missouri 63401, United States
  • Southeastern Research Center LLC
    Winston-Salem, North Carolina 27103, United States
  • Dayton Respiratory Research Center
    Dayton, Ohio 45415, United States
  • Temple University School of Medicine
    Philadelphia, Pennsylvania 19140, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • Renovatio Clinical-Respiratory & Sleep Disorders Specialists
    The Woodlands, Texas 77005, United States
  • University of Texas Health Science Center at Tyler
    Tyler, Texas 75708, United States
  • LHSC - Victoria Hospital
    London, Ontario N6A 5W9, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Jul 2020, 52 months.

Results were first posted in Oct 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2015
First posted
Aug 18, 2015
StartActual
Mar 8, 2016
Primary completionActual
Jul 29, 2020
CompletionActual
Jul 29, 2020
Results first posted
Oct 14, 2021
Last update
Oct 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02525861
Responsible party
Sponsor
First posted
Aug 18, 2015
Start date
Mar 8, 2016
Primary completion
Jul 29, 2020
Completion
Jul 29, 2020
Results posted
Oct 14, 2021
Last update
Oct 14, 2021

Study contacts

Study Director
study director · Shire

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion